Freeport-McMoRan (FCX) faced a downward revision from Argus. It displayed
Option frenzy with March 14th options becoming available. Despite full-year 2024 earnings missing expectations, heavy investment has been observed across different wealth management firms like
Geneos, Verde Servicos, Matthews International and Bahur Bank.
KBC Group on the other hand, lowered its stake. FCX's stock hit a new 52-week low, raising concerns whether it's time to sell. On a brighter note, it did outperform competitors on the trading day and is still considered a promising investment in the commodity market. However, there was a dip in its price by 3.13% in January 2025. Q4 2024 earnings call displayed a strong financial growth while the actual Q4 earnings lagged behind market expectations. Investor attention has been heightened in anticipation of Q4 earnings report while
Morgan Stanley revises FCX's price target to $44 down from $55. FCX's stock has sizable institutional ownership, with bullish sentiments from notable investors like
Stanley Druckenmiller and
Howard Marks. Despite the Q4 revenue estimates miss, long-term upside remains in play for FCX.
Freeport-Mcmoran FCX News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Sat, 01 Feb 2025 14:08:12 GMT -
Rating 5
- Innovation -6
- Information 7
- Rumor -2
